Swiss data protection chief pushes back on drug pricing secrecy

SwissInfo

20 August 2020 - A proposed change to the new health insurance law that seeks to keep drug prices under lock and key has raised red flags.

According to news agency Keystone-SDA, Adrian Lobsiger, the Federal Commissioner for Data Protection and Information, has written a letter criticising a confidentiality clause on the price of medicines in the proposed health insurance law.

He argues that the clause contradicts the principle of public access. Lobsiger has already spoken out about his dissatisfaction with the provision and reiterated that it is essential that the public is able to check and monitor the price approval procedure for medicines.

Read SwissInfo article

Michael Wonder

Posted by:

Michael Wonder